Loading clinical trials...
Loading clinical trials...
A Multicenter, Noninterventional, Prospective Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Moderate to Severe Plaque Psoriasis in Daily Practice
Conditions
Interventions
Certolizumab pegol
Locations
79
Belgium
Ps0026 101
Brussels, Belgium
Ps0026 103
Brussels, Belgium
Ps0026 107
Brussels, Belgium
Ps0026 102
Leuven, Belgium
Ps0026 110
Maldegem, Belgium
Ps0026 109
Mons, Belgium
Start Date
August 21, 2019
Primary Completion Date
December 2, 2022
Completion Date
December 2, 2022
Last Updated
January 23, 2023
NCT06979453
NCT07116967
NCT07250802
NCT07449702
NCT07290569
NCT06888193
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions